FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2486690983> ?p ?o ?g. }

• W2486690983 endingPage "2989" @default.
• W2486690983 startingPage "2981" @default.
• W2486690983 abstract "Aims Statins have modest adverse effects on glycaemic control. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers low-density lipoprotein cholesterol. This study assessed the effects of alirocumab on new-onset diabetes and pre-diabetes incidence in individuals without diabetes at baseline.Methods and results Pooled analysis of 10 ODYSSEY Phase 3 trials ( n = 4974) of 24–104 weeks duration. Six trials ( n = 4211) were ≥52 weeks in length. Most patients received background maximally tolerated statin. Alirocumab effect on the rate of diabetes-related treatment-emergent adverse events (TEAEs), and/or fasting plasma glucose (FPG) and glycated haemoglobin A1C (HbA1C) was measured at baseline and every 12–24 weeks. Transition to diabetes analysis combined TEAE and FPG/HbA1C laboratory data. At baseline, 30.7% of individuals had diabetes and were excluded from the current analysis. The remaining 3448 individuals without diabetes had pre-diabetes (39.6%) or were normoglycaemic (29.7%). The hazard ratio (HR; 95% confidence interval) for diabetes-related TEAEs in alirocumab was 0.64 (0.36–1.14) vs. placebo and 0.55 (0.22–1.41) vs. ezetimibe. The HR associated for transition from pre-diabetes to new-onset diabetes for alirocumab was 0.90 (0.63–1.29) vs. placebo and 1.10 (0.57–2.12) vs. ezetimibe. Mean change in FPG/HbA1C over time showed no difference between treatment groups in patients without diabetes.Conclusions There was no evidence of an effect of alirocumab on transition to new-onset diabetes in 3448 individuals without diabetes at baseline with a follow-up period of 6–18 months, compared to either placebo or ezetimibe. Longer follow-up with larger number of individuals is needed to conclusively rule out an effect." @default.
• W2486690983 created "2016-08-23" @default.
• W2486690983 creator A5005414020 @default.
• W2486690983 creator A5007048045 @default.
• W2486690983 creator A5009182471 @default.
• W2486690983 creator A5017195322 @default.
• W2486690983 creator A5025154210 @default.
• W2486690983 creator A5042842097 @default.
• W2486690983 creator A5045462483 @default.
• W2486690983 creator A5080414941 @default.
• W2486690983 creator A5083976399 @default.
• W2486690983 creator A5086336385 @default.
• W2486690983 creator A5089418361 @default.
• W2486690983 date "2016-07-26" @default.
• W2486690983 modified "2023-10-16" @default.
• W2486690983 title "No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies" @default.
• W2486690983 cites W134624138 @default.
• W2486690983 cites W1423581981 @default.
• W2486690983 cites W1934277520 @default.
• W2486690983 cites W1962272706 @default.
• W2486690983 cites W1972661406 @default.
• W2486690983 cites W1985747185 @default.
• W2486690983 cites W2001328643 @default.
• W2486690983 cites W2009200378 @default.
• W2486690983 cites W2018010993 @default.
• W2486690983 cites W2024100456 @default.
• W2486690983 cites W2052703897 @default.
• W2486690983 cites W2064328378 @default.
• W2486690983 cites W2069616685 @default.
• W2486690983 cites W2070668396 @default.
• W2486690983 cites W2097510503 @default.
• W2486690983 cites W2101702589 @default.
• W2486690983 cites W2103108681 @default.
• W2486690983 cites W2103518970 @default.
• W2486690983 cites W2105063571 @default.
• W2486690983 cites W2115169717 @default.
• W2486690983 cites W2121535401 @default.
• W2486690983 cites W2137983259 @default.
• W2486690983 cites W2141898196 @default.
• W2486690983 cites W2155259933 @default.
• W2486690983 cites W2162348815 @default.
• W2486690983 cites W2164750952 @default.
• W2486690983 cites W2175477592 @default.
• W2486690983 cites W2266600614 @default.
• W2486690983 cites W2460967190 @default.
• W2486690983 cites W2596624061 @default.
• W2486690983 cites W3021842026 @default.
• W2486690983 cites W4232648360 @default.
• W2486690983 doi "https://doi.org/10.1093/eurheartj/ehw292" @default.
• W2486690983 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5081037" @default.
• W2486690983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27460890" @default.
• W2486690983 hasPublicationYear "2016" @default.
• W2486690983 type Work @default.
• W2486690983 sameAs 2486690983 @default.
• W2486690983 citedByCount "135" @default.
• W2486690983 countsByYear W24866909832016 @default.
• W2486690983 countsByYear W24866909832017 @default.
• W2486690983 countsByYear W24866909832018 @default.
• W2486690983 countsByYear W24866909832019 @default.
• W2486690983 countsByYear W24866909832020 @default.
• W2486690983 countsByYear W24866909832021 @default.
• W2486690983 countsByYear W24866909832022 @default.
• W2486690983 countsByYear W24866909832023 @default.
• W2486690983 crossrefType "journal-article" @default.
• W2486690983 hasAuthorship W2486690983A5005414020 @default.
• W2486690983 hasAuthorship W2486690983A5007048045 @default.
• W2486690983 hasAuthorship W2486690983A5009182471 @default.
• W2486690983 hasAuthorship W2486690983A5017195322 @default.
• W2486690983 hasAuthorship W2486690983A5025154210 @default.
• W2486690983 hasAuthorship W2486690983A5042842097 @default.
• W2486690983 hasAuthorship W2486690983A5045462483 @default.
• W2486690983 hasAuthorship W2486690983A5080414941 @default.
• W2486690983 hasAuthorship W2486690983A5083976399 @default.
• W2486690983 hasAuthorship W2486690983A5086336385 @default.
• W2486690983 hasAuthorship W2486690983A5089418361 @default.
• W2486690983 hasBestOaLocation W24866909831 @default.
• W2486690983 hasConcept C120665830 @default.
• W2486690983 hasConcept C121332964 @default.
• W2486690983 hasConcept C126322002 @default.
• W2486690983 hasConcept C134018914 @default.
• W2486690983 hasConcept C2778163477 @default.
• W2486690983 hasConcept C2778849439 @default.
• W2486690983 hasConcept C2780072125 @default.
• W2486690983 hasConcept C2780745583 @default.
• W2486690983 hasConcept C2780902209 @default.
• W2486690983 hasConcept C2780948078 @default.
• W2486690983 hasConcept C2994423189 @default.
• W2486690983 hasConcept C43554185 @default.
• W2486690983 hasConcept C555293320 @default.
• W2486690983 hasConcept C61511704 @default.
• W2486690983 hasConcept C71924100 @default.
• W2486690983 hasConceptScore W2486690983C120665830 @default.
• W2486690983 hasConceptScore W2486690983C121332964 @default.
• W2486690983 hasConceptScore W2486690983C126322002 @default.
• W2486690983 hasConceptScore W2486690983C134018914 @default.
• W2486690983 hasConceptScore W2486690983C2778163477 @default.
• W2486690983 hasConceptScore W2486690983C2778849439 @default.
• W2486690983 hasConceptScore W2486690983C2780072125 @default.

• next